Maibo Pharmaceutical-B (02181.HK) announced that China's State Drug Administration (SDA) has approved an application for a clinical trial of CMAB807X (deschumab) in the treatment of bone metastasis of tumors.
CMAB807X is a kind of human IgG2 monoclonal antibody, which is expected to be used to treat bone metastasis of tumor and giant cell tumor of bone and prevent bone related events in patients with solid tumor bone metastasis and multiple myeloma after the application of new drug is approved.